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Ulcerative colitis (UC) is a chronic inflammatory colonic dis-
ease with repetitive episodes of remission and relapse. Although 
the precise etiology of UC remains unclear, interactions between 
the immune system and the environment and, in particular, in-
teractions between the genetic make-up and gut microbiota are 
considered to be the main factors responsible for UC develop-
ment.1 Recently, the therapeutic options for UC have increased, 
and several biologic agents, including anti-tumor necrosis fac-
tor (anti-TNF) agents (infliximab, certolizumab pegol, adalim-
umab, and golimumab) and anti-integrin molecules (natalizumab 
and vedolizumab), are now available in clinical practice.2 These 
biologic agents could be an optimal choice for the treatment of 
patients with moderately to severely active UC who have not 
been successfully treated with conventional therapies consisting 
of steroids and/or immunomodulators.3,4 In the absence of head-
to-head trials, recently, two network meta-analyses have been 
conducted to compare the efficacy of various biologic agents in 
the treatment of moderately to severely active UC. Danese et al.5 
showed that biologic agents (adalimumab, golimumab, inflix-
imab, and vedolizumab) were superior to a placebo in terms of 
induction or maintenance of clinical remission and suggested 
that infliximab is more likely to induce a favorable clinical 
outcome than adalimumab. Stidham et al.6 demonstrated that 
biologic agents (infliximab, adalimumab, and golimumab) are 
effective in the induction and maintenance of remission of UC 
and showed that no single agent is clinically superior to any 
other.
Adalimumab is a fully human IgG1 monoclonal antibody 
against TNF-α. Phase III trials in patients with moderately to 
severely active UC have demonstrated the safety and efficacy 
of adalimumab in inducing and maintaining clinical remis-
sion at an induction dose of 160/80 mg (week 0/week 2) and a 
maintenance dose of 40 mg every other week.7,8 Colombel et al.9 
showed that long-term treatment with adalimumab for up to 4 
years is well tolerated and is beneficial for patients with moder-
ately to severely active UC. Based on these results, adalimumab 
has been approved worldwide for the treatment of adult patients 
with moderately to severely active UC. 
When deciding upon a biologic agent, several parameters 
including patient preference, potential for immunogenicity, and 
cost-effectiveness as well as comparative efficacy and safety 
should be considered. Because adalimumab is administered sub-
cutaneously and requires a short time for therapy, which con-
sists of a single injection, this agent can be used conveniently 
and easily at home. A prospective survey to assess the prefer-
ences of patients for selecting anti-TNF agents revealed that the 
majority of patients preferred agents that were administered by 
subcutaneous injection rather than by intravenous infusion.10 
Associations between immunogenic events (such as infusion 
reactions and loss of response) and antibodies to infliximab or 
adalimumab have been demonstrated. According to data from 
Ben-Horin et al.,11 antiadalimumab antibodies do not cross-react 
with infliximab, and switching between infliximab and adalim-
umab is often advocated when the response to one drug is lost. 
Cost issues might also guide treatment choice. However, data on 
the cost-effectiveness of biologic agents are still lacking. 
Recently, Zhang et al.12 reported a meta-analysis of the ef-
ficacy and safety of adalimumab for patients with moderately 
to severely active UC who are unresponsive to conventional 
therapies. In that study, three randomized controlled trials were 
included to compare the efficacy and safety of adalimumab to a 
placebo. The authors revealed that adalimumab was more effec-
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tive than the placebo in producing clinical remission, a clinical 
response, and mucosal healing, and inflammatory bowel disease 
questionnaire responses at week 8 and week 52 without signifi-
cant severe side effects. These results suggest that adalimumab 
is an effective option for inducing and maintaining clinical 
remission in patients with moderately to severely active UC who 
are unresponsive to conventional therapies. The combined use 
of infliximab and thiopurine therapy was superior to inflix-
imab monotherapy in patients with UC who were naïve to both 
agents.2 Zhang et al.12 showed that adalimumab was superior 
to a placebo at week 8 in patients with UC receiving immuno-
modulator therapy, whereas similar remission rates at week 8 
were observed in the adalimumab and placebo groups who were 
not receiving immunomodulator therapy. These results indicate 
that the combination of adalimumab and an immunomodulator 
might be superior to adalimumab monotherapy in patients with 
UC. 
In the absence of head-to-head trials, these results could 
be helpful in choosing adalimumab as a treatment option for 
patients with moderately to severely active UC. However, this 
study has some limitations; the number of included studies was 
relatively small, and the analyzed follow-up period was not lon-
ger than 1 year. Furthermore, randomized clinical comparative 
studies differ from real-life clinical practice with regard to vari-
ous conditions, such as inclusion and exclusion criteria, disease 
severity, and indications. Therefore, further systematic reviews 
and meta-analyses including long-term follow up and real-
life clinical data are needed to clarify the role of adalimumab 
in patients with moderately to severely active UC. Moreover, 
head-to-head comparison studies would ultimately produce a 
concrete conclusion for choosing appropriate anti-TNFs and im-
munomodulators.
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